Finally, in addition to its potential role as a predictive biomarker for cancer, claudin-3 has also been shown to bind clostridium perfringens enterotoxin, subsequently leading to toxin-mediated cytolysis, prompting some to suggest that this may indicate a future therapy in select cases of prostate cancer[31,32]. This evidence concerns the gene CLDN3 and cancer.